Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments

BACKGROUND: The introduction of biological disease-modifying anti-rheumatic drugs into clinical practice has dramatically improved the clinical outcomes of individuals with rheumatoid arthritis (RA). We are conducting the IFX-SIRIUS STUDY I that evaluates whether switching from originator infliximab...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Toshimasa, Kawashiri, Shin-Ya, Sato, Shuntaro, Morimoto, Shimpei, Minoda, Shuri, Kawazoe, Yurika, Kuroda, Shohei, Tashiro, Shigeki, Sumiyoshi, Remi, Hosogaya, Naoki, Yamamoto, Hiroshi, Kawakami, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
6900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593062/
https://www.ncbi.nlm.nih.gov/pubmed/32769882
http://dx.doi.org/10.1097/MD.0000000000021480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593062/
https://www.ncbi.nlm.nih.gov/pubmed/32769882
http://dx.doi.org/10.1097/MD.0000000000021480

Ejemplares similares